Abstract Extracellular ATP and its hydrolysis product, adenosine, acting through specific receptors collectively named purinergic receptors, regulate female fertility by influencing the endometrial fluid microenvironment. There are four major groups of ecto-nucleotidases that control the levels of extracellular ATP and adenosine and thus their availability at purinergic receptors: ecto-nucleoside triphosphate diphosphohydrolases (E-NTPDases), ecto-nucleotide pyrophosphatase/phospho-diesterases (E-NPPs), ecto-5′-nucleotidase (5′NT), and alkaline phosphatases (APs). The aim of the present work is to characterize the expression and distribution of ecto-nucleotidases in human endometrium along the menstrual cycle and after menopause, to evaluate their potential utility as fertility markers. We examined proliferative, secretory and atrophic endometria from women without endometrial pathology undergoing hysterectomy. We show that the ecto-nucleotidases are mainly present at endometrial epithelia, both luminal and glandular, and that their expression fluctuates along the cycle and also changes after menopause. An important result was identifying NPP3 as a new biological marker of tubal metaplasia. Our results emphasize the relevance of the study of purinergic signaling in human fertility.
Introduction
During the menstrual cycle, in response to autocrine, paracrine and endocrine factors, the human endometrium undergoes morphological and functional changes essential for uterine receptivity, affecting glands, stroma and luminal epithelium. The first phase is characterized by a proliferative endometrium and is governed by estrogens, while after ovulation, the secretory phase, influenced by progesterone, prepares the endometrium for embryo implantation [1] .
Extracellular nucleotides, such as ATP, and nucleosides, such as adenosine, are autocrine and paracrine molecules that play important roles in reproduction [2] . In the uterus, extracellular ATP is needed for the initiation and maintenance of myometrial contractions [3] ; it contributes to the regulation of the uterine fluid microenvironment by regulating endometrial Cl − secretion [4] , Na + absorption [5] and cervical mucus production [6] . P2X and P2Y nucleotide receptors have been identified in the female reproductive tract [7] [8] [9] , with changes in the expression along the cycle [10] and during implantation [11] and pregnancy [8] . Furthermore, extracellular ATP treatment of sperm improves its fertilizing capability [12] [13] [14] , thus potentially improving the outcome of assisted reproduction techniques.
Extracellular adenosine, the dephosphorylated product generated from the hydrolysis of ATP, coordinates early post-implantation events [15] , and also exerts control of myometrium contractions [16] . Importantly, adenosine is a key molecule for sperm capacitation, the series of changes that sperm undergo in the female reproductive tract to acquire fertilizing ability [17] [18] [19] .
For the reasons stated above, the study of the mechanisms controlling the levels of extracellular ATP and adenosine in the female reproductive system, the endometrium in particular, is necessary. The concentrations of extracellular ATP and adenosine are controlled by specific nucleotidehydrolyzing enzymes expressed at the cell surface called ecto-nucleotidases [20] . Different families of enzymes are responsible for these activities and, alone or acting sequentially, they generate adenosine from adenine nucleotides (i.e., ATP, ADP or AMP): (1) the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family includes four plasma membrane-bound members: NTPDase1 (CD39), NTPDase2, NTPDase3 and NTPDase8 [21] [22] [23] ; these enzymes are differentially expressed and hydrolyze nucleoside triphosphates and diphosphates to their monophosphate derivatives; (2) the ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) family has three members (NPP1-3) capable of hydrolyzing nucleoside triphosphates to monophosphates and PPi, such as ATP to AMP and PPi [24] ; (3) the 5′-nucleotidase family has only one member attached to the outer plasma membrane, the ecto-5′-nucleotidase (CD73), a glycosyl phosphatidylinositol-linked membrane-bound glycoprotein that efficiently hydrolyzes AMP to adenosine [25] ; (4) the alkaline phosphatase (AP) family includes ubiquitous enzymes, such as the placental AP (PLAP) and the tissue nonspecific AP (TNAP), with broad substrate specificity, including adenine nucleotides and pyrophosphate, releasing inorganic phosphate [26] . The generated adenosine can be further inactivated by other enzymes such as adenosine deaminase (ADA), which can be expressed as a soluble ectoenzyme, or as membrane-associated enzyme often forming larger complexes with CD26/dipeptidyl peptidase IV, converting adenosine to inosine. Moreover, ATP can be re-synthesized via backward ecto-phosphotransfer reactions catalyzed by enzymes such as adenylate kinase and nucleoside diphosphate kinase [23] .
In spite of their obvious importance, very little is known of the ecto-nucleotidases expression in endometrium. A few studies have been conducted in mice; NTPDase1 and 2 were identified in myometrium [27] , and ecto-5′-nucleotidase in endometrium, where the expression and activity fluctuate along the estrous cycle and with pregnancy, pointing to hormonal regulation of extracellular adenosine levels in this organ [28, 29] . However, to our knowledge, there are no available data concerning the expression of ecto-nucleotidases in human endometrium and their possible changes along the cycle.
The study of protein expression in remodeling cyclic human endometrium, and its comparison to postmenopausal endometrium, is crucial for understanding the physiology of reproduction. In the present work, we characterize for the first time the expression of human endometrial nucleotideconverting ectoenzymes, in both cyclic and postmenopausal endometria.
Methods

Samples
The ethical principles of this study adhere to the Declaration of Helsinki, and all the procedures were approved by the ethics committee for clinical investigation of Bellvitge Hospital. Endometrial samples were obtained from hysterectomy specimens without endometrial malignancy at the Service of Gynecology of Bellvitge Hospital. Fresh samples were cut, embedded in O.C.T freezing media (Tissue-Tek®; Sakura Finetk, Zoeterwoude, the Netherlands), snap-frozen in a Shandon Histobath™ 2 (Neslab Instruments Inc., USA) at the Service of Pathology and stored at −80°C until used. Alternatively endometrial samples were obtained from the Tumor Bank of Bellvitge Biomedical Research Institut (IDIBELL).
Eight proliferative, 12 secretory and 32 atrophic endometria were used in this study. Endometrial dating was done at the Service of Pathology.
Demographic description of the samples and the factors that indicated the need for hysterectomy are summarized in Table 1 .
Reagents
Primary antibodies used in this study are listed in Table 2 . Secondary antibodies used were: horseradish peroxidaseconjugated goat anti-mouse (EnVision™ + system; DAKO, Carpinteria, CA, USA), Alexa Fluor 488-or 555-goat antimouse or anti-rabbit, and Alexa Fluor 488-donkey anti-goat (Life Technologies, Paisley, UK). To-Pro®-3 (Life Technologies) was used as a nuclear marker.
Immunolabeling experiments Sections (10 μm) were obtained with the Cryostat Leica CM1950 (Leica, Wetzlar, Germany), put onto poly-L-lysine covered glass slides, and fixed in 10 % phosphate-buffered formalin mixed with cold acetone (Merck, Darmstadt, Germany) for 2.5 min.
For immunolabeling experiments samples were rinsed with PBS and pre-incubated for 1 h at room temperature (RT) with PBS containing either 20 % normal goat serum or 20 % horse serum (Gibco, Paisley, UK) and 0.2 % gelatin (Merck). Slices were then incubated overnight at 4°C with the primary antibodies at the dilutions indicated in Table 2 . All dilutions were made in PBS. After three washes in PBS, tissue sections were incubated with the suitable secondary antibodies for 1 h at RT. Secondary antibodies alone were routinely included as controls for the experiments. Nuclei were counterstained with haematoxylin or, alternatively, in fluorescence assays, To-Pro®-3 was used to visualize the nuclei.
Samples were observed and photographed under light Leica DMD 108 microscope or under Leica TCS-SL spectral confocal microscope (Leica).
Immunohistochemical staining was independently evaluated by at least two observers. Staining distribution was recorded. Label intensity was scored as negative (−), weak (+), intermediate (++) or strongly positive (+++).
In situ AMPase and ATPase activity experiments
For the histochemical localization of AMPase and ATPase activity, the Wachstein/Meisel lead phosphate method [29, 30] was performed. Briefly, fixed tissue sections were preincubated for 1 h at RT in 50 mM Tris-maleate buffer, pH 7.4 containing 2 mM CaCl 2 and 0.25 M sucrose. Enzymatic reaction was performed for 1 h at 37°C in the same buffer supplemented with 5 mM MnCl 2 , 2 mM Pb(NO 3 ) 2 , 3 % Asterisk in the TNAP column of secretory endometrium indicates that the label is only present in a narrow area of the stroma subjacent to luminal epithelium and atrophic (c, f, i) endometria. PLAP and TNAP were immunodetected in the glands (arrows) of all types of endometrium, and in the luminal epithelium of proliferative an atrophic endometria (filled arrowheads). TNAP was also immunodetected at the stroma subjacent to the luminal epithelium in secretory endometrium (e, empty arrowheads). Microphotographs g, h, and i show blue deposits corresponding to AP in situ activity and nuclei are stained in green. Inset in h corresponds to the activity experiment in the presence of the inhibitor levamisole, and shows complete AP inhibition. Scale bars0100 μm dextran T250 and 2.5 mM levamisole, as an inhibitor of the AP activity, and in the presence of either 1 mM AMP or 200 μM ATP as a substrate. For CD73 inhibition experiments, 1 mM α,β-methylene-ADP (α,β-meADP) was added to both pre-incubation and enzymatic reaction buffers. The substrate was omitted in the control experiments. The reaction was revealed by incubation with 1 % (NH 4 ) 2 S v/v for exactly 1 min, and nuclei were counterstained with haematoxylin. Samples were then dehydrated, mounted with DPX mounting medium, and observed and photographed under light Leica DMD 108 microscope.
In situ alkaline phosphatase activity experiments
The histochemical localization of AP was addressed by using the Gossrau method [31] Results Table 3 compiles the results of all the immunolabelings performed.
Our results show that PLAP and TNAP were expressed in both luminal and glandular epithelia of endometrium (Fig. 1 ), but were absent in the luminal epithelium of secretory endometria. Moreover, in this type of endometrium, TNAP was present in the stroma subjacent to the luminal epithelium. Besides this change in the enzyme distribution, there were no other significant variations along the cycle or when compared with the atrophic endometrium. Immunolabeling was stronger for TNAP than for PLAP in all the mentioned structures, especially in glands, where the PLAP staining was very weak. In situ activity experiments demonstrated AP activity in the locations of the immunodetected proteins, and this activity was completely inhibited with the i An activity experiment performed on atrophic endometrium in the presence of the inhibitor α,β-meADP, and shows complete inhibition of AMPase activity. Note that 5′-NT expression and AMPase activity are stronger in the glands of basal layer (arrows) and that myometrium is also intensely labeled (asterisks). Scale bars0100 μm AP inhibitor levamisole, confirming the specificity of the activity. As expected, AP was also detected in endothelial cells.
Ecto-5′-nucleotidase (CD73) was expressed and active in glandular epithelium and in stroma in both cyclic and atrophic endometria (Fig. 2) . Labeling in the basal layer glands was much more intense than in the functional layer. Luminal epithelium was not stained. In situ activity experiments demonstrated AMPase activity in the structures where the enzyme was immunodetected, and this activity was completely inhibited by the specific ecto-5′-nucleotidase inhibitor α,β-meADP. Although the enzyme is present throughout the cycle, an increase in the expression and activity in the stroma was consistently observed in the secretory phase.
As expected, NTPDase1 (CD39) was expressed in the endothelial cells of the stromal blood vessels (Fig. 3a) . Sparse cells at the stroma were also positive for NTPDase1 staining, probably being macrophages and other immune system cells. Labeling was never seen in association with either glands or luminal surface. On the contrary, NTPDase3 was expressed by glandular and luminal epithelia, in both cyclic and atrophic endometria. An increase in the expression in both epithelia was observed in the secretory phase. These changes in the expression in glands are represented in Fig. 3b . Interestingly, NTPDase3 was also detected in the endometrial spiral arteries. This expression is associated with the muscle layer but not with the endothelium as confirmed by double immunostainings performed with anti-SMA and anti-CD31 antibodies, respectively (Fig. 4) . NTPDase3 was not detected in the myometrial arteries or in other blood vessels. The in situ ATPase activity was detected in the above reported structures, coinciding with NTPDase1 and NTPDase3 expression (Fig.  3c) . NTPDase2 was not detected in endometrial epithelia, neither luminal nor glandular (data not shown).
NPP1 was expressed in luminal epithelia of all types of endometrium and in glands of proliferative and especially atrophic endometrium, and was absent in secretory endometrium (Fig. 5a ). NPP3 was expressed in glands only in cyclic endometria but with marked changes in the amount of expression along the cycle, being maximal in the secretory Fig. 3 a Immunolocalization of NTPDase1 (a, b, c) and NTPDase3 (d, e, f, g) in proliferative (a, d), secretory (b, e, f) and atrophic (c, g) endometria. NTPDase1 was immunodetected in the stromal blood vessels of all types of endometrium. NTPDase3 was immunodetected in the luminal and glandular epithelia of all types of endometria. Note that label is stronger in the secretory (e, f) than in the proliferative endometrium (d) and that in atrophic endometrium label is also very high. NTPDase3 was also immunodetected in spiral arteries (inset in d). Scale bars0100 μm except for the inset, where it is 25 μm. b Label intensity score of NTPDase3 in the glandular epithelium of proliferative, secretory and atrophic endometria. Maximal score is found in secretory and atrophic endometria. c ATPase in situ histochemistry in glands (arrowheads) and in stroma, especially in blood vessels (arrows). The inset corresponds to an activity experiment performed in the absence of substrate. Scale bar0100 μm phase (Fig. 5b) . These changes in glandular NPP3 expression are represented in Fig. 5c . NPP3 was also expressed in luminal epithelium exclusively in secretory endometria. Importantly, no labeling was seen in atrophic endometria except in cases of tubal metaplasia where strong labeling was seen in association with metaplastic glands (Fig. 5b) . NPP2 was not detected in endometrial epithelia, neither luminal nor glandular (data not shown).
CD26 was detected in endometrial glands, with maximal expression in the secretory phase, coinciding with previous and atrophic (c) endometria, and in a case of tubal metaplasia (d) in an atrophic endometrium. NPP3 was immunodetected in the luminal and glandular epithelia of cyclic endometria (a, b) but is maximal at the secretory phase (b). Note that the label is absent in the atrophic endometrium (c), and that it is present in the tubal metaplastic gland (d). Arrowheads point to the cilia in the tubal metaplastic epithelium. Scale bars0100 μm (a-c) and 25 μm (d). c Label intensity score of NPP3 in the glandular epithelium of proliferative, secretory and atrophic endometria. Maximal score is found in secretory endometria findings [32] . We add here new information by studying also the postmenopausic endometria, showing that CD26 is only weakly expressed in these endometria (Fig. 6) . It is noticeable that in atrophic endometria, CD26 expression is not homogeneous amongst all the glands and that only a few glands were positive for this labeling. Immunostaining was also detected in the endothelial cells. Figure 7 illustrates an endometrium showing the location of all the ecto-enzymes studied here.
Discussion
Extracellular ATP and adenosine, acting through purinergic receptors, are signaling molecules playing a role in reproduction. Purinergic receptors have already been identified in endometrium with a variety of roles, such as ion transport, mucus secretion, cell proliferation and innate mucosal immunity. However, to date little has been known about the ectoenzymes that regulate their ligand concentrations in human endometrium. In the present work, we have extensively characterized the expression of different families of ectonucleotidases in cyclic and postmenopausic endometria. Our results show that different enzymes, operating in concert or consecutively, are able to metabolize extracellular ATP to adenosine. These enzymes thus have the potential to modulate ligand availability for both nucleotide and nucleoside receptors, making them key molecules in the purinergic signaling of endometrium. In this section, we discuss in detail our findings for each family of enzymes.
Mammalian APs are ubiquitous enzymes that display broad substrate specificity towards phosphate compounds. In the rat, AP activity has been already described in uterine luminal and glandular epithelium, establishing a correlation between the luminal activity and endometrial sensitivity [33] . Moreover, a local increase in AP activity has been shown to occur at the site of blastocyst implantation, as part of the early decidual response [34] . These enzymes are thought to be involved in the attachment of blastocyst to the endometrium and in the maintenance of the composition and volume of luminal secretion essential for embryo development [35] . Studies of APs in relation to fertility have also been conducted in women showing up-regulation of the PLAP-2 gene as a marker of ongoing pregnancy after in vitro fertilization treatment [36] . In the present work, we localize the expression and activity of two AP enzymes, PLAP and TNAP, at the luminal and glandular epithelium of human endometrium. Our results coincide with previous studies [37, 38] , and we add new data by comparing the expression along the cycle and in postmenopausic endometrium. We did not detect any significant quantitative variations in protein expression in glands, but changes in the distribution of PLAP and TNAP expression were consistently found in the luminal part of secretory endometria, where both enzymes were absent. Moreover, in these endometria, a new location for TNAP was seen at the stroma subjacent to the lumen. These variations might be related with changes needed for appropriate embryo attachment and implantation occurring mainly at the luminal part of the endometrium.
Ecto-5′-nucleotidase, an enzyme efficiently hydrolyzing AMP to adenosine, has already been identified in the mouse female reproductive tract, with marked changes in endometrial expression along the estrous cycle [29] , and in pregnancy [28] . Besides a function in the regulation of uterine fluid composition, a role for this enzyme in the generation of extracellular adenosine needed for sperm capacitation has been postulated [39] [40] [41] . We show here that in human endometrium ecto-5′-nucleotidase is expressed in glands, with more intensity in the basal layer, and in the stroma, but not in luminal epithelium. The stroma displayed changes in the expression along the cycle, being maximal at the secretory phase. In situ AMPase activity, in the presence or absence of the specific inhibitor α,β-meADP, confirmed that the immunodetected protein was active in the above mentioned structures. Moreover, it is highly probable that the adenosine generated by this AMPase activity and accumulated in the stroma is involved in the regulation of cyclical inflammation physiologically occurring in endometrium [42] . Ecto-5′-nucleotidase might well act sequentially, after NTPDase1, an ecto-nucleotidase also present in the stroma. ) and atrophic (c, f) endometria. CD26 was immunodetected in the blood vessels (arrows) and in glandular epithelia of secretory endometrium (b, e). Note that only a few isolated glands are labeled in atrophic endometrium (c, empty arrowheads). Scale bars0500 μm (a, b) and 100 μm (c-f). b Label intensity score of CD26 in the glandular epithelium of proliferative, secretory and atrophic endometria. Maximal score is found in secretory endometria NTPDase3 is expressed in luminal and glandular epithelia. NTPDase3 was already identified in other secretory epithelial cells from mouse reproductive organs such as epididymis, prostate and oviducts [27, 43] . We report here for the first time the expression of NTPDase3 in relation to blood vessels. This expression, however, is limited to the muscle layer of spiral arteries, without expression in the myometrial arteries, a fact that enhances the importance of this finding since NTPDase3 can be considered as a new marker of human spiral arteries. Spiral artery remodeling plays a central role in establishing and maintaining a normal pregnancy, and impaired remodeling is involved in common pregnancy disorders such as recurrent pregnancy loss and pre-eclampsia, a major complication of pregnancy and one of the leading causes of maternal and perinatal morbidity and mortality. In spite of the obvious importance, very little is known of the mechanisms responsible for this remodeling, and characterizing these arteries phenotypically has important implications for this understanding [44, 45] .
The NPP family of enzymes has already been identified in epithelial cells, in relation with ion transport, amongst other functions [24] . Here we see that NPP1 and NPP3 are expressed in glandular epithelia with changes among endometrium types. Interestingly, the expression of both enzymes seems to be coordinated along the cycle; when there is less expression of one enzyme, there is greater expression of the other. Furthermore, NPP3 is exclusively expressed in glandular and luminal epithelia of cyclic endometria showing maximal expression in secretory endometria; NPP3 therefore becomes a biological marker of this type of endometrium. These marked Fig. 7 Model of the human endometrium showing differential distribution of ecto-enzymes in surface and glandular epithelia, stromal cells and spiral arteries. Letters in parentheses indicate that the enzyme was only detected in proliferative (p), secretory (s) or atrophic (a) endometria differences between NPP3 expression in cyclic and postmenopausic endometria point to a relation with fertility and further studies would be of interest for human fertility. Moreover, our results demonstrate that NPP3 is a new marker of endometrial tubal metaplasia. This finding is clinically relevant for the diagnostic of this adaptive phenomenon, usually overlapped with pathological changes, and frequently overlooked and misdiagnosed [46] . CD26 has already been identified in female reproductive organs such as the placenta, ovary and endometrium, and a possible role as adhesion molecule in human blastocyst implantation has been proposed [47] . The fact that ecto-ADA is often associated in larger complexes with CD26 leads us to include the study of CD26 expression in the present work. Here we show that CD26 is highly expressed in secretory endometria and that is almost absent in atrophic endometria, also pointing to its possible implication in women fertility.
A simplified overview of our findings, including the different endometrial structures studied, is presented in Fig. 7 . This study provides important new information about the regulation of purinergic signaling by ecto-nucleotidases in human endometria, and opens up the field for further investigation of their role in human fertility and in endometrial pathology.
